Research on psychedelics has found that the substances could be effectively used to treat various mental health conditions, including post-traumatic stress disorder and anxiety. But, what other therapeutic and medical benefits do psychedelics possess that may help humanity?
Making organ transplants safer
Ischemia-reperfusion injury, commonly referred to as IRI, occurs when organ tissues are damaged after being deprived of oxygen for some time. The inury can affect organs such as the brain, kidneys, lungs and the heart, and it mainly plagues patients who have undergone organ transplants. Physicians use machine perfusion and ischemic pre- and post-conditioning to reduce or prevent IRI. However, these strategies are not fully effective.
DMT, which is a psychedelic that possesses anti-inflammatory properties, has shown potential in preventing IRI occurrence. The effectiveness and use of this psychedelic in organ transplant procedures may greatly enhance survival rates.
Effectively managing treatment-resistant depression
The majority of individuals who suffer from major depressive disorder respond to treatments. However, about 30% of these patients don’t respond to anti-depression treatments.
Research has found that ketamine significantly improves depressive symptoms and is also efficacious in decreasing suicidal ideation.
Curbing eating and obesity disorders
The CDC estimates that roughly 43% of Americans are obese, which increases the risk of certain cancer types, type 2 diabetes, stroke and heart disease. Obesity is a serious and common ailment that impacts millions of individuals across the globe.
Research has found that psilocybin may help curb an individual’s cravings and decrease their appetite, which may make them eat less.
In addition to this, psilocybin may also be used to treat patients with eating disorders such as bulimia nervosa and anorexia nervosa. Trials on the compound’s effectiveness in treating eating disorders are currently in motion in various research institutes.
Treating rare types of cancer
A patent application by PharmaTher relates to the use of psilocybin in treating acute myeloid leukemia, kidney neoplasms, breast neoplasms, melanoma and liver carcinoma. While research on this is scarce, it does give patients hope, given that the aforementioned cancers have no or suboptimal treatment options.
Treating eye ailments
Research has found that DMT possess the potential to treat eye ailments such as glaucoma. Glaucoma is known to cause blindness and/or vision loss by damaging the optic nerve. The illness impacts more than 2.5 million Americans aged 40 and above.
Present treatments include eye drops, which induce side effects such as stinging and redness. These treatments also require multiple daily applications, which makes it harder for individuals to comply with it.
Many more unique medicinal uses for psychedelic compounds are likely to be discovered given that companies such as Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) have vast product pipelines at different stages of development.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.